FILE - In this Thursday, April 8, 2021 file photo, the Johnson & Johnson COVID-19 vaccine sits on a table at a pop up vaccinations site the Albanian Islamic Cultural Center, in the Staten Island borough of New York. The U.S. is recommending a “pause” in administration of the single-dose Johnson & Johnson COVID-19 vaccine to investigate reports of potentially dangerous blood clots. (AP Photo/Mary Altaffer, File)

The rollout of Johnson & Johnson Janssen COVID-19 vaccine rollout will resume, Ministry of Health announced yesterday.
The decision to continue the rollout came after the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee for Immunization Practices (ACIP) last week reaffirmed that the Johnson & Johnson Janssen COVID-19 vaccine is recommended for persons 18 years of age.
“The benefits of the vaccine far outweigh the risks. MOH will resume the administration of the J&J vaccine and provide comprehensive education at the vaccination site.”
Earlier the CDC recommended a pause on the administration of the vaccines after six reported U.S. cases of cerebral venous sinus thrombosis (CVST), a rare type of blood clot, in individuals after receiving the J&J vaccine.
The MOH said that of 197 doses of the J&J vaccines administered from March to early April 2021 in Palau, “no adverse reactions have been reported to the Ministry of Health or the vaccination team.”
As of April 26, 8,787 total persons have been fully vaccinated and 12,082 people are partially vaccinated. The MOH COVID-19 Situation Report also stated that 49 percent of the population are fully vaccinated. Vaccines so far are only administered to persons 18 years old and above. (B. Carreon)

Leave a comment

Your email address will not be published. Required fields are marked *